Clinical Trials Audit Preparation

Regular price €104.99
Title
Quantity:
In stock with our UK publisher. 14-28 days
Delivery/Collection within 10-20 working days
14 days return policy Shipping & Delivery
A01=Vera Mihajlovic-Madzarevic
audit
Author_Vera Mihajlovic-Madzarevic
boards
book
Category=MBGR1
clinical
drug
eq_isMigrated=1
eq_nobargain
explanation
fda
gcp
good clinical
guide
institutional
manufacturing
musthave
parties
pharmaceutical companies
practice
preparation
prepare
process
professional
research
stepbystep
tedious

Product details

  • ISBN 9780470248850
  • Weight: 517g
  • Dimensions: 163 x 244mm
  • Publication Date: 18 Jun 2010
  • Publisher: John Wiley & Sons Inc
  • Publication City/Country: US
  • Product Form: Hardback
Secure checkout Fast Shipping Easy returns
A must-have guide for any professional in the drug manufacturing industry

The Good Clinical Practice (GCP) audit is a tedious but necessary exercise that assures that all parties do their job properly and in compliance with the applicable FDA code. Clinical Trials Audit Preparation demystifies the audit process for all parties involved, including clinical research sponsors, clinical investigators, and institutional review boards.

This book provides a step-by-step explanation of the FDA audit procedures for clinical trials and of how pharmaceutical companies, clinical investigators, and institutional review boards should prepare for regulatory audits. The book emphasizes the processes and procedures that should be implemented before a clinical audit occurs, making this an imperative guide to any professional in the drug manufacturing industry, including drug manufacturing companies, regulatory affairs personnel, clinical investigators, and quality assurance professionals.

Among the topics discussed:

  • Good Clinical Practices and therapeutic product development in clinical research

  • The roles of the sponsor of a clinical investigation, the IRB, or independent ethics committee

  • The roles and responsibilities of the clinical trial investigator

  • The inspection preparation

  • The Audit Report and the Form 483

  • Warning letters issued to clinical investigators and clinical trial sponsors and their impact on product development

VERA MIHAJLOVIC-MADZAREVIC has more than twenty years of experience in scientific and clinical research in the academia and industry. She is the Director of Global Research Pharma Canada. She conducts Good Clinical Practice (GCP) audits for the pharmaceutical, biotech, and medical device industries worldwide in compliance with FDA, Health Canada, and other regulations. She also trains clinical and scientific personnel in GCP and clinical research, leading the Training and Professional Development Programs at the Clinical Research Institute of America (criamerica.com) and the Academy of Applied Pharmaceutical Sciences.

More from this author